title: Authors' reply to Scheper and Lijfering.
authors.affiliation: Department of Internal Medicine, University of Toronto, Toronto, ON, Canada.
authors.forename: Michael
authors.initials: M
authors.lastname: Fralick
authors.affiliation: Sunnybrook Health Sciences Centre, Toronto, ON, Canada, M4N 3M5 david.juurlink@ices.on.ca.
authors.forename: David N
authors.initials: DN
authors.lastname: Juurlink
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000892:Anti-Infective Agents, Urinary / Q000009:adverse effects*; D003645:Death, Sudden / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008297:Male; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects*
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000892:Anti-Infective Agents, Urinary; D015662:Trimethoprim, Sulfamethoxazole Drug Combination